GGT, the membrane enzyme that recycles glutathione
Gamma-glutamyl transferase (GGT) is a membrane-bound enzyme found on the outer surface of many cells, especially in the liver and bile ducts. It is produced by liver cells and bile duct lining cells, with smaller amounts in kidney, pancreas, and intestine. A GGT blood test measures how much of this enzyme has entered the circulation from these tissues, giving a window into activity at the liver–bile duct interface. The measured enzyme mostly originates from the hepatobiliary system.
In the body, GGT drives the recycling of the antioxidant glutathione by transferring its gamma‑glutamyl group to amino acids (the gamma‑glutamyl cycle). This helps move amino acids across cell membranes, preserves glutathione stores, and supports detoxification and oxidative stress defenses. Because these actions are concentrated in the liver and bile ducts, circulating GGT reflects the state of membrane turnover and enzyme activity in those structures. In short, GGT links amino-acid handling with glutathione metabolism, and its blood level mirrors that biology.
Why GGT tracks bile flow, detox load, and oxidative stress
Gamma-glutamyl transferase (GGT) is a membrane enzyme that recycles glutathione, the body’s main antioxidant, and is concentrated in the liver and bile ducts. Because it tracks both bile flow and oxidative stress, GGT is a sensitive window into hepatobiliary function, metabolic health, and whole‑body redox balance.
Big picture: GGT links the liver–bile axis to antioxidant defenses and metabolic signaling. Its trajectory over time integrates exposures (alcohol, drugs), fatty liver biology, and vascular risk, making it a useful marker for long‑term hepatic and cardiometabolic outcomes.
How low, in-range, and elevated GGT values usually read
Most laboratories report a fairly narrow adult reference range; in healthy adults, values near the lower end tend to reflect minimal liver enzyme induction and lower oxidative stress. Very low values are usually benign. Exceptionally low results are rare and, when due to an inherited enzyme deficiency, are typically recognized in childhood with metabolic or neurologic features rather than in healthy adults.
When GGT rises, it usually indicates stress in the liver or bile ducts—cholestasis, obstruction, fatty liver, or enzyme induction from alcohol or certain medications. People may feel well or notice fatigue, itching, jaundice, dark urine, or pale stools if bile flow is impaired. GGT often climbs alongside alkaline phosphatase; when both are elevated, the source is typically hepatobiliary rather than bone. Persistently higher GGT correlates with insulin resistance and cardiometabolic risk, not just liver disease.
Men often have slightly higher values than women. During pregnancy, GGT typically remains normal or low even as alkaline phosphatase rises. Pediatric ranges vary with age.
Low values usually reflect minimal enzyme induction and low oxidative stress—common in healthy individuals, more typical in women, and can be lower in pregnancy. They rarely indicate special pediatric disorders where cholestasis occurs with low GGT. In adults, very low GGT is generally not a concern.
Being in range suggests intact hepatobiliary function, unobstructed bile flow, and balanced redox status. Epidemiology associates values in the lower-to-mid part of the reference interval with favorable cardiometabolic profiles.
High values usually reflect increased bile-duct pressure or enzyme induction from liver stress. This occurs with impaired bile flow (cholestasis or obstruction), fatty liver, alcohol-related injury, viral hepatitis, pancreatobiliary disease, medication induction, or congestive hepatopathy. GGT often rises with alkaline phosphatase in bile-duct conditions and may rise alone with enzyme-inducing exposures. Even without overt liver disease, higher GGT correlates with insulin resistance, type 2 diabetes, and cardiovascular events, indicating higher oxidative and metabolic strain.
Age, sex, pregnancy, and drug-induced shifts
GGT varies by age (higher with aging) and sex (higher in men), and tends to stay normal or slightly lower in pregnancy. Enzyme-inducing drugs (for example, certain anticonvulsants) and alcohol can elevate it. Reference intervals differ by lab and method. Context with ALT, AST, ALP, and bilirubin improves interpretation.
Where GGT fits in the wider liver and metabolic panel
GGT is most informative read with ALT, ALP, bilirubin, and metabolic markers like triglycerides and fasting glucose. This combination distinguishes hepatocellular from cholestatic patterns and clarifies whether elevations reflect alcohol, medications, fatty liver, or bile-duct pathology.
FAQs
GGT testing measures the concentration of the GGT enzyme in blood to assess liver and bile duct stress and to provide context for oxidative and metabolic strain.
Testing helps detect early liver or biliary stress, differentiate liver versus bone sources of alkaline phosphatase, and track the impact of alcohol, medications, and lifestyle changes.
Frequency depends on goals and risk factors. Periodic testing is useful for trend tracking, especially during changes in alcohol use, weight, diet, exercise, or medications known to affect the liver.
Alcohol intake, cholestasis or bile duct obstruction, nonalcoholic fatty liver disease, certain medications, metabolic stress, age, and sex differences can influence levels. GGT often remains normal in pregnancy even if alkaline phosphatase rises.
Most GGT tests do not require special preparation. Follow any instructions provided with your test, and aim for consistency in timing and recent alcohol intake when comparing trends.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Whitfield, J. B. (2001). Gamma glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences, 38(4), 263-355. https://doi.org/10.1080/20014091084227
- Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. The American Journal of Gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517
- Long, Y., Zeng, F., Shi, J., Tian, H., & Chen, T. (2014). Gamma-glutamyltransferase predicts increased risk of mortality: A systematic review and meta-analysis of prospective observational studies. Free Radical Research, 48(6), 716-728. https://doi.org/10.3109/10715762.2014.902055
- Giannini, E. G., Testa, R., & Savarino, V. (2005). Liver enzyme alteration: A guide for clinicians. CMAJ, 172(3), 367-379. https://doi.org/10.1503/cmaj.1040752
- Newsome, P. N., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., Hall, R., Harrower, U., Hudson, M., Langford, A., Mackie, A., Mitchell-Thain, R., Sennett, K., Sheron, N. C., Verne, J., Walmsley, M., & Yeoman, A. (2018). Guidelines on the management of abnormal liver blood tests. Gut, 67(1), 6-19. https://doi.org/10.1136/gutjnl-2017-314924






































.avif)
